Literature DB >> 12907461

Promoter but not exon 7 polymorphism of endothelial nitric oxide synthase affects training-induced correction of endothelial dysfunction.

Sandra Erbs1, Yves Baither, Axel Linke, Volker Adams, Yanwen Shu, Karsten Lenk, Stephan Gielen, Rainer Dilz, Gerhard Schuler, Rainer Hambrecht.   

Abstract

UNLABELLED: Background- Polymorphisms in the promoter (T-786C) and exon 7 (G894T) of the endothelial nitric oxide synthase (eNOS) gene were shown to be associated with reduced vascular NO production or increased proteolytic cleavage of eNOS. Therefore, we aimed to determine the effects of these polymorphisms on endothelial function and endothelial response to physical exercise in patients with coronary artery disease (CAD). METHODS AND
RESULTS: Sixty-seven patients were randomized to either a training or a control group. At the beginning and after 4 weeks, acetylcholine-induced changes in average peak velocity (APV) of a coronary or mammary artery were invasively assessed by Doppler velocimetry. Polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism. At the beginning, in subjects with the wild-type (WT) variant, APV increased by 88+/-7% in response to acetylcholine. This response was significantly blunted in patients who were positive for the promoter (44+/-7%) or the exon 7 (62+/-9%) polymorphism. Four weeks of exercise training resulted in augmentation of an endothelium-dependent increase in APV by +36+/-12% in promoter polymorphism-positive patients but by +81+/-18% and +91+/-15% in WT variant- and exon 7 polymorphism-positive subjects, respectively.
CONCLUSIONS: These results suggest that the presence of either one of the polymorphisms attenuates endothelium-dependent vasodilatation in CAD patients. Only the promoter polymorphism might have an adverse effect on training-induced improvement in endothelial function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907461     DOI: 10.1161/01.ATV.0000090128.11465.18

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Haplotype analysis of the endothelial nitric oxide synthase gene in relation to acute myocardial infarction.

Authors:  J Chen; S Su; J Huang; X Zhou; Y Wang; R Chen; D Gu
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

2.  Effects of aerobic exercise on the blood pressure, oxidative stress and eNOS gene polymorphism in pre-hypertensive older people.

Authors:  Anderson Saranz Zago; Joon-Young Park; Nicola Fenty-Stewart; Leonardo Reis Silveira; Eduardo Kokubun; Michael D Brown
Journal:  Eur J Appl Physiol       Date:  2010-07-08       Impact factor: 3.078

3.  No evidence for an association between the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and fibromyalgia syndrome.

Authors:  Belgin Alaşehirli; Seniz Demiryürek; Emine Arica; Savaş Gürsoy; Abdullah T Demiryürek
Journal:  Rheumatol Int       Date:  2006-09-02       Impact factor: 2.631

4.  Genetics and cardiovascular system: influence of human genetic variants on vascular function.

Authors:  Rodrigo Gonçalves Dias; Márcia Maria Gowdak; Alexandre Costa Pereira
Journal:  Genes Nutr       Date:  2010-11-03       Impact factor: 5.523

5.  Impaired regulation of neuronal nitric oxide synthase and heart rate during exercise in mice lacking one nNOS allele.

Authors:  E J F Danson; K S Mankia; S Golding; T Dawson; L Everatt; S Cai; K M Channon; D J Paterson
Journal:  J Physiol       Date:  2004-05-21       Impact factor: 5.182

6.  Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study.

Authors:  Ignacio Cruz-González; Esther Corral; María Sánchez-Ledesma; Angel Sánchez-Rodríguez; Cándido Martín-Luengo; Rogelio González-Sarmiento
Journal:  BMC Cardiovasc Disord       Date:  2009-08-04       Impact factor: 2.298

Review 7.  Genetic Regulation of Endothelial Vasomotor Function.

Authors:  Seung Kyum Kim; Michael P Massett
Journal:  Front Physiol       Date:  2016-11-25       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.